Literature DB >> 7339866

Postischaemic hyperaemia studied with a transcutaneous oxygen electrode used at 33-37 degrees C.

U Ewald, G Rooth, T Tuvemo.   

Abstract

The hyperaemic response in the vasculature of the forearm skin following induced ischaemia was studied with a transcutaneous oxygen (tcpO2) electrode. Electrode temperatures of 35-37 degree C allowed optimal recordings of the postischaemic reaction. During arterial occlusion there was a fall in tcpO2 to zero in 1-3 min. Re-establishment of circulation resulted in a biphasic reaction, with a steep rise overshooting the baseline recording by 1-3 kPa and a slower return to baseline level. At higher electrode temperatures (greater than 39 degree C) there was no overshoot due to hyperaemia. The postischaemic peak response was well reproducible from one occasion to another in the same subject. Simultaneous recording of energy consumption for the heating of the electrode permitted detection of artifacts and environmental changes unrelated to postischaemic hyperaemia, therefore validating the tcpO2 recordings but only at electrode temperatures greater than 35 degree C. The tcpO2 technique used at 35-37 degree C easily detects relative blood flow changes and seems suitable for comparative studies. The method is non-invasive and permits continuous recordings in well-defined skin areas in human subject; significant advantages compared with other methods available.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7339866     DOI: 10.3109/00365518109090509

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  2 in total

1.  Reduced transcutaneous oxygen tension and impaired vascular response in Type 1 (insulin-dependent) diabetes.

Authors:  R Railton; P Newman; J Hislop; A D Harrower
Journal:  Diabetologia       Date:  1983-10       Impact factor: 10.122

2.  Cardiac and microcirculatory effects of different doses of prostaglandin E1 in man.

Authors:  J H Wilkens; H Wilkens; B Elger; F Cassidy; L Caspary; A Creutzig; J C Frölich
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.